Trigeminal Neuralgia (Tic Douloureux) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Trigeminal neuralgia is a chronic pain condition that affects the trigeminal nerve, which carries sensation from face to brain. Symptoms include spontaneous attacks of pain or attacks triggered by things such as touching the face, chewing, speaking, and brushing teeth, pain in areas supplied by the trigeminal nerve, including the cheek, jaw, teeth, gums, lips, or less often the eye and forehead.
The Trigeminal Neuralgia (Tic Douloureux) Drugs in Development market research report provides an overview of the Trigeminal Neuralgia (Tic Douloureux) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Trigeminal Neuralgia (Tic Douloureux), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Trigeminal Neuralgia (Tic Douloureux) and features dormant and discontinued projects.
Trigeminal Neuralgia Pipeline Drugs Market Targets
The targets of the Trigeminal Neuralgia pipeline drugs market are Calcitonin Gene Related Peptide Type 1 Receptor, Metabotropic Glutamate Receptor 5, Sodium Channel Protein Type 9 Subunit Alpha, Sodium Dependent Dopamine Transporter, Cannabinoid Receptor 1, Cannabinoid Receptor 2, Gamma-Aminobutyric Acid Receptor Subunit Alpha 6 (GABA, Peroxisome Proliferator Activated Receptor Gamma, Sodium Channel Protein Type 8 Subunit Alpha, Transient Receptor Potential Cation Channel Subfamily A Member 1, and Transient Receptor Potential Cation Channel Subfamily V Member 4.
Trigeminal Neuralgia pipeline drugs market, by targets
For more target insights, download a free report sample
Mechanisms of Action of Trigeminal Neuralgia Pipeline Drugs Market
Some of the mechanisms of action of the Trigeminal Neuralgia pipeline drugs market are Calcitonin Gene Related Peptide Type 1 Receptor Antagonist, Metabotropic Glutamate Receptor 5 Antagonist, Sodium Dependent Dopamine Transporter Inhibitor, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, Gamma-Aminobutyric Acid Receptor Subunit Alpha 6 (GABAAgonist, Peroxisome Proliferator Activated Receptor Gamma Agonist, Sodium Channel Protein Type 8 Subunit Alpha Blocker, Sodium Channel Protein Type 9 Subunit Alpha Blocker, and Sodium Channel Protein Type 9 Subunit Alpha Inhibitor.
Trigeminal Neuralgia pipeline drugs market, by mechanisms of action
For more mechanisms of action insights, download a free report sample
Routes of Administration in Trigeminal Neuralgia Pipeline Drugs Market
The routes of administration in the Trigeminal Neuralgia pipeline drugs market are oral, topical, intravenous, ophthalmic, subcutaneous, buccal, inhalational, intraocular, nasal, and sublingual.
Trigeminal Neuralgia pipeline drugs market, by routes of administration
For more routes of administration insights, download a free report sample
Molecule Types in Trigeminal Neuralgia Pipeline Drugs Market
The molecule types in the Trigeminal Neuralgia pipeline drugs market are small molecule, antisense oligonucleotide, gene therapy, monoclonal antibody, protein, and recombinant protein.
Trigeminal Neuralgia pipeline drugs market, by molecule types
For more molecule type insights, download a free report sample
Key Trigeminal Neuralgia Pipeline Drugs Market Companies
Some of the key companies in the Trigeminal Neuralgia pipeline drugs market are Initiator Pharma AS, Noema Pharma AG, Acasti Pharma Inc, Amgen Inc, Biogen Inc, Biohaven Pharmaceutical Holding Company Ltd, Coda Biotherapeutics Inc, Hoba Therapeutics ApS, InMed Pharmaceuticals Inc, and Noveome Biotherapeutics Inc.
Trigeminal Neuralgia pipeline drugs market, by key companies
To know more about key companies, download a free report sample
Market report overview
Targets | Calcitonin Gene Related Peptide Type 1 Receptor, Metabotropic Glutamate Receptor 5, Sodium Channel Protein Type 9 Subunit Alpha, Sodium Dependent Dopamine Transporter, Cannabinoid Receptor 1, Cannabinoid Receptor 2, Gamma-Aminobutyric Acid Receptor Subunit Alpha 6 (GABA, Peroxisome Proliferator Activated Receptor Gamma, Sodium Channel Protein Type 8 Subunit Alpha, Transient Receptor Potential Cation Channel Subfamily A Member 1, and Transient Receptor Potential Cation Channel Subfamily V Member 4 |
Mechanisms of Action | Calcitonin Gene Related Peptide Type 1 Receptor Antagonist, Metabotropic Glutamate Receptor 5 Antagonist, Sodium Dependent Dopamine Transporter Inhibitor, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, Gamma-Aminobutyric Acid Receptor Subunit Alpha 6 (GABAAgonist, Peroxisome Proliferator Activated Receptor Gamma Agonist, Sodium Channel Protein Type 8 Subunit Alpha Blocker, Sodium Channel Protein Type 9 Subunit Alpha Blocker, and Sodium Channel Protein Type 9 Subunit Alpha Inhibitor |
Routes of Administration | Oral, Topical, Intravenous, Ophthalmic, Subcutaneous, Buccal, Inhalational, Intraocular, Nasal, and Sublingual |
Molecule Types | Small Molecule, Antisense Oligonucleotide, Gene Therapy, Monoclonal Antibody, Protein, and Recombinant Protein |
Key Companies | Initiator Pharma AS, Noema Pharma AG, Acasti Pharma Inc, Amgen Inc, Biogen Inc, Biohaven Pharmaceutical Holding Company Ltd, Coda Biotherapeutics Inc, Hoba Therapeutics ApS, InMed Pharmaceuticals Inc, and Noveome Biotherapeutics Inc |
Scope
This report provides:
- A snapshot of the global therapeutic landscape of Trigeminal Neuralgia (Central Nervous System).
- Reviews of pipeline therapeutics for Trigeminal Neuralgia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which include product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
- Reviews of key companies involved in Trigeminal Neuralgia (Central Nervous System) therapeutics and enlists all their major and minor projects.
- Evaluation of Trigeminal Neuralgia (Central Nervous System) targeted therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA), and molecule type.
- All the dormant and discontinued pipeline projects.
- Reviews of the latest news and deals related to pipeline therapeutics for Trigeminal Neuralgia (Central Nervous System).
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Trigeminal Neuralgia (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Trigeminal Neuralgia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Amgen Inc
Biogen Inc
Biohaven Pharmaceutical Holding Company Ltd
Coda Biotherapeutics Inc
Hoba Therapeutics ApS
Initiator Pharma AS
InMed Pharmaceuticals Inc
Noema Pharma AG
Noveome Biotherapeutics Inc
OliPass Corporation
Oxford Cannabinoid Technologies Ltd
Praxis Precision Medicines Inc
USA Elixiria Biotech Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the targets of the Trigeminal Neuralgia pipeline drugs market?
The targets of the Trigeminal Neuralgia pipeline drugs market are Calcitonin Gene Related Peptide Type 1 Receptor, Metabotropic Glutamate Receptor 5, Sodium Channel Protein Type 9 Subunit Alpha, Sodium Dependent Dopamine Transporter, Cannabinoid Receptor 1, Cannabinoid Receptor 2, Gamma-Aminobutyric Acid Receptor Subunit Alpha 6 (GABA, Peroxisome Proliferator Activated Receptor Gamma, Sodium Channel Protein Type 8 Subunit Alpha, Transient Receptor Potential Cation Channel Subfamily A Member 1, and Transient Receptor Potential Cation Channel Subfamily V Member 4.
-
What are the mechanisms of action of the Trigeminal Neuralgia pipeline drugs market?
Some of the mechanisms of action of the Trigeminal Neuralgia pipeline drugs market are Calcitonin Gene Related Peptide Type 1 Receptor Antagonist, Metabotropic Glutamate Receptor 5 Antagonist, Sodium Dependent Dopamine Transporter Inhibitor, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, Gamma-Aminobutyric Acid Receptor Subunit Alpha 6 (GABAAgonist, Peroxisome Proliferator Activated Receptor Gamma Agonist, Sodium Channel Protein Type 8 Subunit Alpha Blocker, Sodium Channel Protein Type 9 Subunit Alpha Blocker, and Sodium Channel Protein Type 9 Subunit Alpha Inhibitor.
-
What are the routes of administration in the Trigeminal Neuralgia pipeline drugs market?
The routes of administration in the Trigeminal Neuralgia pipeline drugs market are oral, topical, intravenous, ophthalmic, subcutaneous, buccal, inhalational, intraocular, nasal, and sublingual.
-
What are the molecule types in the Trigeminal Neuralgia pipeline drugs market?
The molecule types in the Trigeminal Neuralgia pipeline drugs market are small molecule, antisense oligonucleotide, gene therapy, monoclonal antibody, protein, and recombinant protein.
-
Which are the key companies in the Trigeminal Neuralgia pipeline drugs market?
Some of the key companies in the Trigeminal Neuralgia pipeline drugs market are Initiator Pharma AS, Noema Pharma AG, Acasti Pharma Inc, Amgen Inc, Biogen Inc, Biohaven Pharmaceutical Holding Company Ltd, Coda Biotherapeutics Inc, Hoba Therapeutics ApS, InMed Pharmaceuticals Inc, and Noveome Biotherapeutics Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.